

Ref: FOI/GS/ID 6321

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

20 October 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to the treatment of melanoma and breast cancer.

You asked:

- 1. How many patients are currently (past 3 months) undergoing treatment for melanoma, and how many of these are BRAF+ ?*
- 2. For patients currently (past 3 months) under treatment for melanoma*
 - a. How many patients are Stage IIIa?*
 - b. How many patients are Stage III resectable?*
 - c. How many Stage III patients received a complete resection in the past 3 months?*
- 3. In the past 3 months, how many melanoma patients were treated with the following:*
 - a. Bevacizumab*
 - b. Cobimetinib*
 - c. Dabrafenib*
 - d. Dabrafenib AND Trametinib*
 - e. Dacarbazine*
 - f. Encorafenib AND Binimetinib*
 - g. Ipilimumab*
 - h. Ipilimumab AND Nivolumab*
 - i. Nivolumab*
 - j. Pembrolizumab*
 - k. Trametinib*
 - l. Vemurafenib*
 - m. Vemurafenib AND Cobimetinib*
 - n. Other active systemic anti-cancer therapy*
 - o. Palliative care only*

4. In the past 3 months how many patients were treated with the following for breast cancer?

- a. Abemaciclib + Anastrozole/Exemestane/Letrozole
- b. Abemaciclib + Fulvestrant
- c. Alpelisib + Fulvestrant
- d. Atezolizumab
- e. Bevacizumab
- f. Eribulin
- g. Everolimus + Exemestane
- h. Fulvestrant as a single agent
- i. Gemcitabine + Paclitaxel
- j. Lapatinib
- k. Neratinib
- l. Olaparib
- m. Palbociclib + Anastrozole/Exemestane/Letrozole
- n. Palbociclib + Fulvestrant
- o. Pertuzumab + Trastuzumab + Docetaxel
- p. Ribociclib + Anastrozole/Exemestane/Letrozole
- q. Ribociclib + Fulvestrant
- r. Talazoparib
- s. Transtuzumab + Paclitaxel
- t. Transtuzumab as a single agent
- u. Trastuzumab emtansine
- v. Any other active systemic anti-cancer therapy

Trust response:

1. & 2.

The Trust only undertakes subsequent oncology treatments as the diagnosis and first definitive treatment would be managed by the relevant local Dermatology service.

Therefore, we cannot answer with more detail. From July to September, the Trust started subsequent treatment for four melanoma patients - 2 x Radio Therapy and 2 x Chemotherapy.

3.

Bevacizumab	0
Cobimetinib	0
Dabrafenib	0
Dabrafenib AND Trametinib	1
Dacarbazine	0
Encorafenib AND Binimetinib	0
Ipilimumab	0
Ipilimumab AND Nivolumab	0
Nivolumab	1
Pembrolizumab	0
Trametinib	0
Vemurafenib	0
Vemurafenib AND Cobimetinib	0

Other active systemic anti-cancer therapy	0
Palliative care only	0

4.

Abemaciclib + Anastrozole/Exemestane/Letrozole	0
Abemaciclib + Fulvestrant	0
Alpelisib + Fulvestrant	0
Atezolizumab	0
Bevacizumab	0
Eribulin	0
Everolimus + Exemestane	0
Fulvestrant as a single agent	0
Gemcitabine + Paclitaxel	0
Lapatinib	0
Neratinib	0
Olaparib	1
Palbociclib + Anastrozole/Exemestane/Letrozole	7
Palbociclib + Fulvestrant	8
Pertuzumab + Trastuzumab + Docetaxel	4
Ribociclib + Anastrozole/Exemestane/Letrozole	0
Ribociclib + Fulvestrant	0
Talazoparib	0
Transtuzumab + Paclitaxel	0
Transtuzumab as a single agent	1
Trastuzumab emtansine	0
Any other active systemic anti-cancer therapy	33